
Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY
This indication is approved based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). EMRELIS is a c-Met- …